Demecarium bromide

Demecarium bromide
Clinical data
Trade namesHumorsol
Routes of
administration		Topical (ophthalmic solution)
ATC code
Identifiers
IUPAC name
  • Trimethyl-[3-[methyl-[10-[methyl-(3-trimethylammoniophenoxy)carbonyl-amino]decyl]carbamoyl]oxyphenyl]ammonium dibromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.274
Edit this at Wikidata
Chemical and physical data
FormulaC32H52Br2N4O4
Molar mass716.600 g·mol−1
3D model (JSmol)
SMILES
  • [Br-].[Br-].O=C(Oc1cccc(c1)[N+](C)(C)C)N(CCCCCCCCCCN(C(=O)Oc2cccc(c2)[N+](C)(C)C)C)C
InChI
  • InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2 checkY
  • Key:YHKBUDZECQDYBR-UHFFFAOYSA-L checkY
 ☒NcheckY (what is this?)  (verify)

Demecarium bromide, trade name Humorsol, is a carbamate parasympathomimetic drug that acts as an acetylcholinesterase inhibitor, and is used as a glaucoma medication. It is applied directly to the eye in order to reduce elevated intraocular pressure associated with glaucoma.[1]

Demecarium causes constriction of the pupil (miosis), which improves the drainage of the fluid in the eye (aqueous humour).[2] As demecarium reversibly inhibits cholinesterase, it can be administered less frequently than other parasympathomimetic drugs, such as carbachol.[3]

Commercially produced demecarium bromide solution, previously sold under the trade name Humorsol,[4] is no longer available,[3] although solutions of demecarium can be compounded.[5]

Use in dogs

When administered with a topical corticosteroid, demecarium can delay the onset of primary glaucoma in dogs.[3] High doses of demecarium may cause organophosphate toxicity, particularly if flea treatments containing organophosphates are administered at the same time.[3]

See also

References

  1. ↑ Jeske AH, ed. (2014). "Demecarium bromide". Mosby's dental drug reference (11th ed.). St. Louis, Missouri: Elsevier Mosby. p. 374. ISBN 978-0-323-16916-5.
  2. ↑ Stein HA, Stein RM, Freeman MI (2012). Ophthalmic dictionary and vocabulary builder for eye care professionals (4th ed.). New Delhi: Jaypee Brothers Medical. p. 103. ISBN 9789350253656.
  3. 1 2 3 4 Maggs DJ, Miller PE, Ofri R (2013). "Indirect-acting parasympathomimetic agents". Slatter's Fundamentals of Veterinary Ophthalmology (5th ed.). St. Louis, Missouri: Elsevier. p. 51. ISBN 978-1-4377-2367-0.
  4. ↑ Edmunds MW, Mayhew MS (2013). Pharmacology for the primary care provider (4th ed.). Elsevier Health Sciences. p. 174. ISBN 978-0-323-08790-2.
  5. ↑ Alario AF, Strong TD, Pizzirani S (November 2015). "Medical Treatment of Primary Canine Glaucoma". The Veterinary Clinics of North America. Small Animal Practice. 45 (6): 1235–59, vi. doi:10.1016/j.cvsm.2015.06.004. PMID 26319445.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.